MX2012001513A - Uso de melanocortinas para tratar la dislipidemia. - Google Patents

Uso de melanocortinas para tratar la dislipidemia.

Info

Publication number
MX2012001513A
MX2012001513A MX2012001513A MX2012001513A MX2012001513A MX 2012001513 A MX2012001513 A MX 2012001513A MX 2012001513 A MX2012001513 A MX 2012001513A MX 2012001513 A MX2012001513 A MX 2012001513A MX 2012001513 A MX2012001513 A MX 2012001513A
Authority
MX
Mexico
Prior art keywords
melanocortins
treat dyslipidemia
dyslipidemia
alcoholic
treat
Prior art date
Application number
MX2012001513A
Other languages
English (en)
Spanish (es)
Inventor
Michael Dewitt Culler
Heather A Halem
Original Assignee
Ipsen Pharma Sas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ipsen Pharma Sas filed Critical Ipsen Pharma Sas
Publication of MX2012001513A publication Critical patent/MX2012001513A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
    • A61K38/34—Melanocyte stimulating hormone [MSH], e.g. alpha- or beta-melanotropin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/665—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
MX2012001513A 2009-08-05 2010-07-30 Uso de melanocortinas para tratar la dislipidemia. MX2012001513A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US27348809P 2009-08-05 2009-08-05
PCT/US2010/043832 WO2011017209A1 (en) 2009-08-05 2010-07-30 Use of melanocortins to treat dyslipidemia

Publications (1)

Publication Number Publication Date
MX2012001513A true MX2012001513A (es) 2012-05-22

Family

ID=43544604

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2012001513A MX2012001513A (es) 2009-08-05 2010-07-30 Uso de melanocortinas para tratar la dislipidemia.

Country Status (12)

Country Link
US (2) US20120135923A1 (https=)
EP (1) EP2461681A4 (https=)
JP (1) JP2013501053A (https=)
KR (1) KR20120059520A (https=)
CN (1) CN102548399A (https=)
AU (1) AU2010279719A1 (https=)
BR (1) BR112012002445A2 (https=)
CA (1) CA2769883A1 (https=)
IN (1) IN2012DN01493A (https=)
MX (1) MX2012001513A (https=)
RU (1) RU2012108110A (https=)
WO (1) WO2011017209A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0819188B1 (pt) 2007-11-05 2021-06-22 Ipsen Pharma S.A.S. Uso de melanocortinas para a preparação de um medicamento para tratar resistência à insulina
US20120226018A1 (en) * 2009-11-16 2012-09-06 Ipsen Pharma, S.A.S. Process for the Synthesis of Ac-Arg-Cyclo(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH2
BR112013027222B1 (pt) 2011-06-14 2022-07-12 Ipsen Pharma S.A.S. Composição de liberação sustentada que contém peptídeos como ingrediente ativo
LT3539551T (lt) * 2011-12-29 2022-01-10 Rhythm Pharmaceuticals, Inc. Su melanokortino-4 receptoriumi susijusių sutrikimų gydymo būdas heterozigotiniuose nešiotojuose
CN115957297A (zh) 2013-03-15 2023-04-14 节奏制药公司 药物组合物
EP2970388B1 (en) 2013-03-15 2018-07-25 Rhythm Pharmaceuticals, Inc. Peptide compositions
PL3356386T3 (pl) 2015-09-30 2024-08-05 Rhythm Pharmaceuticals, Inc. Sposób leczenia zaburzeń związanych ze szlakiem receptora melanokortyny 4
WO2019219714A1 (en) * 2018-05-15 2019-11-21 Novo Nordisk A/S Compounds capable of binding to melanocortin 4 receptor

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005000217A2 (en) * 2003-06-06 2005-01-06 Merck & Co., Inc. Combination therapy for the treatment of dyslipidemia
CN101052649A (zh) * 2004-11-04 2007-10-10 诺和诺德公司 用于治疗肥胖的肽类
NZ565217A (en) * 2005-07-08 2010-03-26 Ipsen Pharma Sas Melanocortin receptor ligands
JP2009500426A (ja) * 2005-07-08 2009-01-08 ソシエテ・ドゥ・コンセイユ・ドゥ・ルシェルシュ・エ・ダプリカーション・シャンティフィック・エス・ア・エス メラノコルチン受容体のリガンド
TWI364290B (en) * 2007-05-25 2012-05-21 Ipsen Pharma Sas Melanocortin receptor ligands modifled with hydantoin
EP2167112A4 (en) * 2007-06-15 2012-01-25 Ipsen Pharma Sas CYCLIC PEPTIDE MELANOCORTIN RECEPTOR LIGANDS
BRPI0819188B1 (pt) * 2007-11-05 2021-06-22 Ipsen Pharma S.A.S. Uso de melanocortinas para a preparação de um medicamento para tratar resistência à insulina

Also Published As

Publication number Publication date
WO2011017209A1 (en) 2011-02-10
CA2769883A1 (en) 2011-02-10
JP2013501053A (ja) 2013-01-10
CN102548399A (zh) 2012-07-04
EP2461681A1 (en) 2012-06-13
BR112012002445A2 (pt) 2015-10-13
US20130331324A1 (en) 2013-12-12
KR20120059520A (ko) 2012-06-08
US20120135923A1 (en) 2012-05-31
IN2012DN01493A (https=) 2015-06-05
EP2461681A4 (en) 2013-04-24
RU2012108110A (ru) 2013-09-10
AU2010279719A1 (en) 2012-03-01

Similar Documents

Publication Publication Date Title
MX2012001513A (es) Uso de melanocortinas para tratar la dislipidemia.
SG178602A1 (en) Dual variable domain immunoglobulins and uses thereof
PH12012500774A1 (en) Dual variable domain immunoglobulins and uses thereof
PH12012500815A1 (en) Dual variable domain immunoglobulins and uses thereof
MX2012004415A (es) Inmunoglobulinas de dominio variable doble y usos de las mismas.
MX2012001262A (es) Inmunoglobulinas de dominio variable doble y usos de las misma.
MX2011011669A (es) Inmunoglobulinas de dominio variable dual y usos de las misma.
MX2010003013A (es) Inhibicion de angiogenesis.
EP2373692A4 (en) IMMUNOGLOBULINE WITH DOUBLE VARIABLE DOMAIN AND ITS USE
WO2008015383A8 (en) Bmp-9 and bmp-10 and their use in breast and prostate cancer therapies
MY159396A (en) Compositions and methods for antibodies targeting complement protein c5
MX2010008696A (es) Composiciones de proteina estabilizadas.
PH12012502523A1 (en) Dual variable domain immunoglobulins and uses thereof
MA32372B1 (fr) INHIBITEURS DPP-IV à UTILISER DANS LE TRAITEMENT DE LA NAFLD
IN2012DN02081A (https=)
EP2068798A4 (en) METHODS, COMPOSITIONS AND APPARATUSES FOR TREATING INJURIES USING ALTERED PRESSURES FROM ATMOSPHERIC PRESSURES
AP2011005777A0 (en) Methods and compositions related to thioesterase enzymes.
WO2010032059A3 (en) Antibodies directed to cd105 and uses thereof
WO2009049284A3 (en) Compositions and methods for improved glycoprotein sialylation
MX2012001306A (es) Inhibicion de matastasis de tumor.
MX2014004074A (es) Metodo de tratamiento de condiciones del higado utilizando antagonistas de notch2.
WO2012006341A8 (en) Anti-ron antibodies
WO2010097788A3 (en) Visfatin therapeutic agents for the treatment of acne and other conditions
WO2010072740A3 (en) TARGETED BINDING AGENTS DIRECTED TO α5β1 AND USES THEREOF
WO2012170742A3 (en) Treatment and prevention of cancer with hmgb1 antagonists

Legal Events

Date Code Title Description
FA Abandonment or withdrawal